Purpose: BRCAness is defined as the status of homologous recombination deficiency (HRD) in tumor tissue, regardless of the presence of pathogenic germline BRCA1/2 variants. A study employing next-generation sequencing analysis showed that HRD was found relatively frequently in brain metastases of breast cancer patients. One of the methods to assess BRCAness is multiplex ligation-dependent probe amplification (MLPA) assay; however, there have been no studies evaluating BRCAness in brain metastases of breast cancer based on MLPA techniques. Methods: We retrospectively investigated 15 brain metastases of breast cancer that were surgically resected at our hospital from January 2007 to December 2022. To evaluate BRCAness, we employed the MLPA method. Results: Of the 15 patients, five patients (33%) had tumors with BRCAness. Clinicopathological factors of patients with brain metastases with BRCAness were not statistically different from those of patients who possessed tumors without BRCAness. Meanwhile, patients with brain metastases with BRCAness had shorter overall survival compared to those without BRCAness (P = 0.013, BRCAness: median 15 months (95% CI; 2–30) vs non-BRCAness: median 28.5 months (95% CI; 10–60)). Conclusion: In this study, we evaluated BRCAness in brain metastases of breast cancer with the MLPA method and found that about one-third of patients had BRCAness-positive tumors.